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Abstract
Background: Mutations in the substrate of HIV-1 protease, especially changes in the NC/p1 cleavage site, can
directly contribute to protease inhibitor (PI) resistance and also compensate for defects in viral replicative capacity
(RC) due to a drug resistant protease. These NC/p1 changes are known to enhance processing of the Gag protein.
To investigate the capacity of HIV-1 to modulate Gag cleavage and its consequences for PI resistance and RC, we
performed a detailed enzymatic and virological analysis using a set of PI resistant NC/p1 variants (HXB2431V,
HXB2436E+437T, HXB2437T and HXB2437V).
Results: Here, we demonstrate that single NC/p1 mutants, which displayed only a slight increase in PI resistance
did not show an obvious change in RC. In contrast, the double NC/p1 mutant, which displayed a clear increase in
processing efficiency and PI resistance, demonstrated a clear reduction in RC. Cleavage analysis showed that a
tridecameric NC/p1 peptide representing the double NC/p1 mutant was cleaved in two specific ways instead of
one.
The observed decrease in RC for the double NC/p1 mutant (HXB2436E+437T) could (partially) be restored by either
reversion of the 436E change or by acquisition of additional changes in the NC/p1 cleavage site at codon 435 or
438 as was revealed during in vitro evolution experiments. These changes not only restored RC but also reduced PI
resistance levels. Furthermore these changes normalized Gag processing efficiency and obstructed the novel
secondary cleavage site observed for the double NC/p1 mutant.
Conclusions: The results of this study clearly demonstrate that HIV-1 can modulate Gag processing and thereby PI
resistance. Distinct increases in Gag cleavage and PI resistance result in a reduced RC that can only be restored by
amino acid changes in NC/p1 which reduce Gag processing to an optimal rate.
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Background
The Human Immunodeficiency Virus type-1 (HIV-1)
protease (PR) is a crucial enzyme in the viral life cycle.
Its activity is required for the generation of mature
infectious virus particles through the highly regulated
and ordered cleavage of the viral precursor Gag and
GagPol polyproteins. The Gag polyprotein encodes the
structural proteins of the virus, which include matrix
(MA), capsid (CA), nucleocapsid (NC), p6, and two
spacer peptides p2 and p1. The GagPol protein, which is
formed after a ribosomal frameshift event with a fre-
quency of 5-10%, encodes in addition to the structural
proteins the three viral enzymes protease, reverse tran-
scriptase, and integrase.
Since the HIV-1 PR plays such a crucial role in the
viral life cycle, it has proven to be a good target for anti-
retroviral therapy, and the introduction of HIV protease
inhibitors (PI) has been one of the key components in
the success of highly active antiretroviral therapy
(HAART). Unfortunately, virological failure has been
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observed and related to the development of PI resistant
viruses [1-4]. The evolution of PI resistance has been
characterized as a stepwise process in which amino acid
changes in the substrate-binding pocket or at more dis-
tant sites in the viral PR are selected initially. These
amino acid changes directly or indirectly reduce the affi-
nity of the viral PR for the inhibitor, thereby causing PI
resistance. These amino acid changes also affect the
binding of the viral PR to its natural substrate, the Gag
and GagPol polyproteins, and as a consequence many of
these PI resistant variants display a reduced replicative
capacity (RC) as compared to wild-type virus [5-8]. To
compensate for a diminished PR activity and thus for a
reduced RC, PI resistant viruses may select compensa-
tory changes in the viral PR itself or in the substrate of
the viral PR, the Gag polyprotein [8-15]. Within the Gag
polyprotein, compensatory changes have frequently been
observed in the C-terminal region, in particular in the
NC/p1 and p1/p6 cleavage sites [8,10-13,15-17].
More recently, it has been shown that changes in the
NC/p1 cleavage site not only act as compensatory muta-
tions, but can also directly contribute to PI resistance.
In vitro selection experiments with an experimental
high-genetic barrier PI (RO033-4649) resulted in the
selection of K436E and/or I437T/V at the P4’and P5’
positions of the NC/p1 cleavage site in the absence of
mutations in the viral protease [18]. A similar observa-
tion was made by De Meyer et al. who reported the
emergence of viruses carrying mutations in the NC/p1
cleavage site preceding the selection of mutations in the
viral PR during in vitro selection experiments with daru-
navir [19]. Furthermore, we demonstrated that these
NC/p1 changes confer PI resistance by enhancing the
processing of Gag [18]. In addition, it has been demon-
strated that NC/p1 mutations can strongly contribute to
PI resistance in the presence of resistance-associated
mutations in the viral protease besides compensating for
loss in viral replicative capacity and are associated with
therapy failure in vivo [17,20,21].
In this study, we investigated the capacity of HIV-1 to
modulate Gag cleavage and its consequences for PI
resistance and replicative capacity by performing a
detailed enzymatic and virological analysis using a set of
PI resistant NC/p1 variants (HXB2431V, HXB2436E+437T,
HXB2437T and HXB2437V).
Results
Effect of NC/p1 cleavage site mutations on viral RC and
Gag processing
A set of four HIV-1 HXB2 recombinant virus clones
containing NC/p1 resistance mutations described in the
literature and conferring different levels of PI resistance
was generated: HXB2431V; HXB2436E+437T; HXB2437T
and HXB2437V (Figure 1a &1b) [18]. The impact of
these NC/p1 cleavage site changes on viral replicative
capacity was investigated by performing viral replication
curves in SupT1 cells. These experiments demonstrated
that the single NC/p1 mutants (HXB2431V; HXB2437T
and HXB2437V), which displayed only a slight decrease
in PI susceptibility, did not show an obvious change in
replicative capacity, although small differences cannot
be excluded (Figure 1c). In contrast, the double NC/p1
mutant (HXB2436E+437T), which displayed a clear
decrease in PI susceptibility, also demonstrated a clear
reduction in replicative capacity. We previously showed
using quantitative Western blot analysis that this double
NC/p1 mutant not only had an enhanced NC/p1 pro-
cessing, but also an enhanced overall Gag processing
compared to wild-type [18]. In addition to quantitative
Western blotting, we also investigated NC/p1 cleavage
by analysing hydrolysis of tridecameric peptides span-
ning the NC/p1 cleavage site by wild-type PR. Using an
HPLC-based assay, in which peptide hydrolysis was
quantified by peak area integration, it was observed that
the NC/p1 peptide reflecting the original HXB2436E+437T
mutant (ERQANFLGETWPS) was cleaved approxi-
mately 2.4 fold more efficiently than the wild-type NC/
p1 peptide (ERQANFLGKIWPS) (Table 1), which sup-
ports the results of the quantitative Western blot
analysis.
Furthermore, it was observed that cleavage of the
HXB2436E+437T NC/p1 peptide gave rise to four product
peaks after HPLC separation instead of two. Therefore,
the four fragments were collected from preparative
HPLC and examined by amino acid analysis; the results
indicated that the cleavage products are the peptides
ERQAN, ERQANF, LGETWPS, and FLGETWPS, indi-
cating a potential secondary PR cleavage site in the
HXB2436E+437T NC/p1 peptide. LC-MS analysis con-
firmed that these peptides are indeed the correct clea-
vage products. To provide further evidence of their
identity, the peptide products were synthesized and
injected over the column. They yielded the same reten-
tion time as the peaks observed after enzymatic cleavage
by HIV-1 PR.
Evolution of NC/p1 mutants in absence of PI pressure and
its impact on RC and PI resistance
To investigate the evolutionary potential of the NC/p1
mutants in the absence of PI pressure and to investigate
if any reductions in RC could be restored, multiple in
vitro evolution experiments were performed in SupT1
cells. After 10 passages, full Gag and PR were amplified
and sequenced.
For the single NC/p1 mutants with only a slight
increase in PI resistance and no obvious reduction in
RC, no evolution was observed in Gag and PR (data not
shown). The only exception was selection of a R429K
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428 429 430 431 432 433 434 435 436 437 
E R Q A N F L G K I 
GAG AGA CAG GCT AAT TTT TTA GGG AAG ATC 
- - - - - - - - E T
HXB2436E+437T --- --- --- --- --- --- --- G-- -C- 
- - - - - - - - - T
HXB2437T --- --- --- --- --- --- --- --- -C- 
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HXB2437V --- --- --- --- --- --- --- --- --- G-- 
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--- 
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Figure 1 Analysis of PI susceptibility and viral replicative capacity of NC/p1 cleavage site mutants. (A) Sequences of the NC/p1 cleavage
site mutants used in this study. Nucleotide changes and amino acid changes (bold) as compared to the wild-type virus HXB2 are indicated. (B)
Analysis of drug susceptibility of the NC/p1 cleavage site mutants to RO033-4649, lopinavir (LPV), tipranavir (TPV) and ritonavir (RTV). Indicated
are the fold changes in EC50 compared to wild-type. (C) Viral replication curves of the different NC/p1 cleavage site mutants (HXB2
436E+437T,
HXB2437T, HXB2437V and HXB2431V) as compared to the wild-type HXB2. Error bars indicate the standard error of the mean.
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change at the p4 position of the NC/p1 cleavage site in
1 out of 5 experiments starting with HXB2431V. When
performing viral replication curves under modified assay
conditions in which the amount of input 24 was lowered
to discern subtle differences in RC, it was observed that
the selection of the R429K slightly improved the RC of
HXB2431V (Additional file 1). In the control experi-
ments, where HXB2 was cultured in the absence of PI,
also no amino acid changes in Gag or PR were observed.
Remarkably, evolution experiments with the poorly
replicating double NC/p1 mutant, revealed the selection
of amino acid changes in/or near the NC/p1 cleavage site
in all five experiments, while no other changes in Gag or
PR were observed (Figure 2A). Three different evolution-
ary pathways could be observed for the double NC/p1
mutant. The first pathway, which was observed in 2 out
of 5 experiments, was a reversion to wild-type of one of
the NC/p1 cleavage site changes (E436K). The second
pathway, observed in 2 out of 5 experiments, did not
involve reversion but acquisition of an additional change
at the P3’ position of the NC/p1 cleavage site (G435R).
Lastly, the third pathway, observed in 1 out of 5 experi-
ments, resulted in the acquisition of an amino acid
change at the more distant P6’ position of the NC/p1 site
(W438R).
Subsequently, we investigated the impact of these
selected NC/p1 changes on viral RC. Therefore, the C-
terminal part of Gag (p2-NC-p1-p6) and PR was cloned
into HXB2. This resulted in the generation of three clones
with the following changes compared to wild-type HXB2:
HXB2437T, HXB2435R+436E+437T and HXB2436E+437T+438R.
Viral replication curves in SupT1 cells demonstrated
that all variants had an increased RC compared to the ori-
ginal HXB2436E+437T mutant (Figure 2B). Both reversion to
wild-type at codon 436 and the acquisition of an arginine
at either codon 435 or 438 resulted in viruses with an RC
comparable to wild-type HXB2, although small differences
cannot be excluded.
To investigate the effect on PI sensitivity, we deter-
mined the susceptibility to the clinically used PI lopina-
vir and tipranavir and the experimental PI RO033-4649
(Figure 2C). Interestingly, all viruses demonstrated a
reduction in PI resistance. This was most pronounced
for the variant which selected the 435R change. This
variant demonstrated such a reduction in PI resistance
that it became fully PI susceptible and even hypersus-
ceptible for RO033-4649. The other two variants with
either the reversion at codon 436 or the acquisition of
the 438R change still demonstrated some residual PI
resistance.
Evolution of NC/p1 mutants in absence of PI pressure and
its impact on Gag cleavage
To determine whether the restoration of RC observed
during the in vitro evolution experiments of the
HXB2436E+437T mutant affected Gag cleavage, in particu-
lar NC/p1 cleavage, we investigated the proteolytic pro-
cessing of Gag both virologically and enzymatically. We
previously showed using quantitative Western blot analy-
sis that the HXB2436E+437T mutant not only had an
enhanced NC/p1 processing but also had an enhanced
overall Gag processing compared to wild-type [18].
For virological analysis, 293 T cells were transfected
with either a wild-type HXB2 or a NC/p1 mutant clone
in the absence and presence of different concentrations
of RO033-4649. Particle lysates were analyzed by quanti-
tative Western blotting using antisera against NC, capsid
(CA) or matrix (MA), and the relative amount of fully
processed NC, CA or MA was compared to respectively
all NC, CA or MA reactive products.
When the NC/p1 processing of the in vitro evolution
variants at suboptimal RO033-4649 concentrations of 50
and 100 nM was compared to the processing of the ori-
ginal HXB2436E+437T mutant, it was observed that all
selected variants restored NC/p1 processing (Figure 3).
This was most pronounced for the acquisition of 435R,
where processing levels were significantly reduced com-
pared to the original double mutant and even wild-type
(Figure 3E). Similar findings were obtained analysing
overall Gag processing using antisera against MA and
CA (Figure 4; CA data are shown in Additional file 2).
In addition to quantitative Western blotting, we also
investigated NC/p1 cleavage by analysing hydrolysis of
mutant tridecameric peptides spanning the NC/p1 clea-
vage site by wild-type PR. Using an HPLC-based assay,
it was observed that the NC/p1 peptide reflecting the
original HXB2436E+437T mutant (ERQANFLGETWPS)
was cleaved approximately 2.4 fold more efficiently than
the wild-type NC/p1 peptide (ERQANFLGKIWPS)
(Table 1) and gave rise to four product peaks after
HPLC separation instead of two, indicating a novel sec-
ondary cleavage site.
When the cleavage of the in vitro evolution variants was
compared to the cleavage of the original HXB2436E+437T
NC/p1 peptide, it was observed that acquisition of the
438R (ERQANFLGETRPS) significantly returned cleavage
towards wild-type levels (Table 1). Acquisition of the 435R
(ERQANFLRETWPS) also reduced cleavage, although this
reduction was not significant. Furthermore, it was
Table 1 Normalized activity of NC/p1 peptide cleavages
by HIV protease
Virus Peptide Normalized activity (± SD)
Wild-type (HXB2) ERQANFLGKIWPS 100 ± 5.0
436E + 437 T ERQANFLGETWPS 240 ± 3.6
+435R ERQANFLRETWPS 210 ± 18.9
+438R ERQANFLGETRPS 160 ± 6.7
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Figure 2 Evolution of NC/p1 mutants in absence of PI pressure and its impact on RC and PI resistance. (A) Representation of the
evolutionary pathways observed during in vitro evolution experiments with HXB2436E+437T. Nucleotide changes and amino acid changes (bold) as
compared to the wild-type virus HXB2 are indicated. (B) Viral replication curves of the different NC/p1 cleavage site mutants: HXB2437T, HXB2435R
+436E+437T and HXB2436E+437T+438R as observed during in vitro evolution experiments of HXB2436E+437T and compared to wild-type HXB2. Error bars
indicate the standard error of the mean. (C) Representation of the fold increases in phenotypic drug resistance of the different NC/p1 cleavage
site mutants: HXB2437T, HXB2435R+436E+437T and HXB2436E+437T+438R as observed during in vitro evolution experiments of HXB2436E+437T and
compared to wild-type HXB2. Drug susceptibility to the PI RO033-4649, lopinavir (LPV), and tipranavir (TPV) was determined in the multiple cycle
MTT assay.
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observed that both peptides gave rise to only two product
peaks during HPLC analysis. This suggests that the sec-
ondary cleavage site observed for the HXB2436E+437T NC/
p1 peptide was obscured due to the acquisition of either
the 435R or the 438R change.
Molecular modeling and computation of HIV-1 protease-
substrate binding
To investigate whether the changes in the NC/p1 sub-
strate observed during the evolution experiments
affected its binding to the viral PR (i.e. Km effect), mole-
cular modeling was performed. Complexes of wild-type
PR and seven tridecapeptide substrate variants were
modeled and simulated using a 1-ns molecular dynamics
run. The overall structure of the PR/substrate complexes
was stable with a root-mean-square deviation (RMSD)
of the PR backbone of 0.8 - 1.5 Å with respect to the
starting crystal structure (PDB code: 2FNS). Further
analyses were done using the last 500 ps of the simula-
tions to allow for longer equilibration.
Positional fluctuations of substrate residues showed a
pronounced difference between the P3-P3’ residues within
the active site on the one hand and the residues outside
the PR cavity on the other. The former group had a smal-
ler calculated average ADP (atomic displacement para-
meter, formerly B-factor) of 44.9 ± 15.4 Å2, whereas the
latter had a higher average ADP of 103.0 ± 50.5 Å2 (Addi-
tional file 3). The former value could be compared with
B
F
D
A
E
C
Figure 3 Quantitative Western blot analysis of NC/p1 mutants using an anti-NC antibody. Wild-type HXB2 and NC/p1 mutant clones used
to transfect 293 T cells in the absence and presence of different concentrations of RO033-4649. Particle lysates were analyzed by quantitative
Western blotting using an anti-NC antibody. Quantification of the NC-reactive signals and the original Western blots are presented in (A&B) for
HXB2437T, in (C&D) for HXB2436E+437T+438R and in (E&F) for HXB2435R+436E+437T.
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the average experimental ADPs of P3-P3’ residues of 67.5
± 0.9 Å2 from the original crystal structure.
These differences in the flexibility between P3-P3’ and
the flanking substrate residues are reflected in the
spread of the energy contributions of substrate residues
to the PR-substrate interaction, which is larger for the
whole peptide (16.6 kcal/mol) than for the better-loca-
lized P3-P3’ residues only (11.6 kcal/mol) (Additional
file 4). Due to the difficulties in comparing the energies
of the structurally diverse flanking substrate residues, we
have focused on their effect upon the binding of P3-P3’
residues. Overall, with the exception of A431V, the
energy values are within a small range of 3.4 kcal/mol.
Given the systematic errors in the computed values of a
few kilocalories per mole due to approximations in the
molecular model and limited sampling, we have inter-
preted the results with caution. We thus observe the
strongest binding between the HIV-1 PR and the P2
mutated substrate (A431V), whereas considerably
weaker binding occurs with all the other peptides,
including wild-type. However, due to the small differ-
ences in their interaction energy values, it is difficult to
discern differences between the NC/p1 variants that
emerged from the evolution experiments and the origi-
nal HXB2436E+437T variant.
Discussion
In this study, we investigated the capacity of HIV-1 to
modulate Gag cleavage and its consequences for PI
resistance and RC by using a set of PI resistant NC/p1
B
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C
Figure 4 Quantitative Western blot analysis of NC/p1 mutants using a MA antiserum. Wild-type HXB2 and NC/p1 mutant clones used to
transfect 293 T cells in the absence and presence of different concentrations of RO033-4649. Particle lysates were analyzed by quantitative
Western blotting using a MA antiserum. Quantification of the MA-reactive signals and the original Western blots are presented in (A&B) for
HXB2437T, in (C&D) for HXB2436E+437T+438R and in (E&F) for HXB2435R+436E+437T.
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variants (HXB2436E+437T, HXB2437T, HXB2437V and
HXB2431V). The 431 V and 437 V changes have been
observed frequently in relation to PI resistance both in
vitro and in vivo, whereas the 436E + 437 T changes as
well as the 437 T change have only been observed in
vitro so far [18,22-24].
HIV-1 Gag processing is highly regulated and results in
the ordered generation of mature viral proteins. During
the processing of Gag, cleavage of NC/p1 is considered
to be among the last and slowest events [25]. This slow
processing rate of NC/p1 seems to be the consequence of
a suboptimal amino acid sequence, resulting in a subopti-
mal conformation of the NC/p1 site for binding to the
HIV-1 PR [26], as we have also shown in this study. Site-
directed mutagenesis experiments have shown that the
processing rate of NC/p1 can be accelerated by certain
amino acid changes at codon 431 and 432, the P2 and P1
positions of this cleavage site [27]. We previously demon-
strated that under PI selective pressure, the virus may
select amino acid changes in NC/p1 at codons 431, 436
and 437 (the P2, P4’ and/or P5’ positions) which cause PI
resistance due to an enhanced processing of not only
NC/p1, but also Gag [18].
This study shows that viral variants with single NC/p1
resistance mutations, A431V, I437V or I437T with only
low-level PI resistance comparable to resistance levels
observed for single resistance mutations in PR, do not
display an obvious reduction in RC. This is in line with a
study from Pettit et al, demonstrating that site-directed
mutants displaying an enhanced processing rate of NC/
p1 due to amino acid changes at the P1 position of the
NC/p1 site showed significant levels of infectivity. In con-
trast, the viral variant with two amino acid changes at the
NC/p1 site, 436E and 437 T, which displayed more pro-
nounced levels of PI resistance, also demonstrated a clear
reduction in RC. These data suggest that processing of
NC/p1 can be enhanced to a certain level without major
consequences for the RC, but that above this level RC is
severely affected.
This observation is also supported by the in vitro evolu-
tion experiments in which we investigated if the reduced
RC of the double NC/p1 mutant could be restored. In
absence of inhibitor, the reduced viral RC of drug-resis-
tant variants can be (partially) restored by loss of the
drug resistance conferring amino acid changes (E436K;
reversion to wild-type) or acquisition of compensatory
mutations (G435R or W438R; persistence of drug resis-
tance mutations) [28]. Despite the fact that there are con-
straints to the selection of amino acid changes in the NC/
p1 site, because the underlying coding sequence also reg-
ulates the Gag/GagPol ribosomal frameshift, only
changes in the NC/p1 site were selected. This implies
that the reduced RC of the double NC/p1 variant can
only be restored by normalizing NC/p1 cleavage through
selection of changes in this particular site. Indeed, we
demonstrated with both quantitative immunoblotting
and peptide cleavage analysis that all observed changes
reduced NC/p1 and Gag processing. In parallel, PI sus-
ceptibility increased with the largest increase observed
for the compensatory change G435R, which even resulted
in hypersusceptibility to RO033-4649. One could specu-
late that when an enhanced Gag processing leads to PI
resistance a reduction in processing may lead to PI
hypersusceptibility.
Cleavage analysis of the original HXB2436E+437T variant
showed that the model peptide ERQANFLGETWPS can
be cleaved in two specific ways, ERQAN-FLGETWPS and
ERQANF-LGETWPS, to yield the four products ERQAN,
ERQANF, LGETWPS, and FLGETWPS. This shift to
ERQANF-LGETWPS represents a novel cleavage site for
NC/p1, which partly (P2-P1*P1’) mimics the p1-p6 clea-
vage site PGNF*LQSR. This secondary cleavage site may
to some extent explain the higher activity observed for the
HXB2436E+437T peptide compared to the wild-type HXB2
peptide. Unfortunately, it is not possible to determine if
the change in sequence or the secondary cleavage site is
responsible for the higher activity. Selection of either the
435R or 438R change during the evolution experiments
seems to obstruct this novel cleavage site, and in the case
of the 438R it results in a significant reduction in cleavage
activity. Further analysis of the Gag cleavage products in
vivo will be necessary to analyze the possible role of this
putative cleavage site in the maturation of HIV-1 particles.
We have attempted to explain the molecular mechan-
ism underlying the selection of mutations during the
evolution experiments and their effects on Gag proces-
sing, RC and PI susceptibility. Using molecular dynamics
simulations of seven PR-substrate complexes in which
we focused on possible effects on Km, we found that the
P4’-P8’ region of the NC/p1 substrate was very flexible,
which is in line with the lack of corresponding electron
densities in the X-ray structure of the corresponding
complex [29].
The interaction energy calculations showed that the
NC/p1 substrate harbouring the A431V change binds
strongest to the PR, whereas the other substrates were
bound more weakly. Due to the small energy differences,
which are similar in magnitude to the systematic errors,
these could not be sorted further. Our finding that the
substrate with the A431V mutation binds more tightly to
the PR than the wild-type NC/p1 substrate is supported
by previous molecular modeling and may in part explain
the higher Km/kcat value observed for the cleavage of the
mutated peptide [18,30]. The very similar interaction
energies of the P3-P3’ moieties of the other substrates of
the analyzed series could be caused by the fact that the
effect of the flanking P4’-P8’ residues on the binding of
the P3-P3’ residues is very small. One should also bear in
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mind that apart from the effect on Km, the mutations
may influence the barriers of the cleavage reactions and
affect kcat as well. In summary, a molecular description of
the mechanims underlying the effect of substrate muta-
tions on Gag processing is currently at the limit or even
beyond of today’s computational tools.
Conclusions
In conclusion, the results of this study indicate that
HIV-1 can modulate NC/p1 cleavage and thereby PI
susceptibility. We show that processing of NC/p1 can
be enhanced to a certain level without major conse-
quences for RC, but that above this level RC is severely
affected. In addition, we demonstrate that once RC is
reduced, the virus may modulate its NC/p1 sequence by
selecting additional changes that restore Gag processing,
PI susceptibility and RC.
Methods
Cells
SupT1 and MT-2 cells were maintained in RPMI 1640
medium with L-glutamine (BioWhittaker, Verviers, Bel-
gium) supplemented with 10% fetal bovine serum (FBS;
Gibco, Breda, The Netherlands) and 10 μg/ml gentami-
cin (Gibco). 293 T cells were maintained in Dulbecco’s
modified Eagle’s medium (BioWhittaker) supplemented
with 10% FBS and 10 μg/ml gentamicin. All cells were
passaged twice weekly.
Construction of NC/p1 HIV-1 molecular clones
PI resistant viruses harboring NC/p1 changes were gener-
ated during in vitro selection experiments using the
experimental PI RO033-4649 or the common PI ritonavir
[18]. Using the viruses obtained from the in vitro selec-
tions, recombinant viruses were generated as previously
described [31]. This resulted in the generation of four dif-
ferent clones containing the following changes compared
to wild-type HXB2: HXB2431V (A431V), HXB2436E+437T
(K436E + I437T), HXB2437T (I437T + A15T in p6pol), and
HXB2437V (I437V) (Figure 1A).
Generation of recombinant viruses
To generate recombinant viruses, NC/p1 molecular clones
were transfected in 293 T cells. For this, 5-6 × 106 293
T cells were seeded the day prior to transfection to achieve
90-95% confluence on the day of transfection. For trans-
fection, 10 μg of plasmid DNA and Lipofectamine 2000
(Invitrogen) were used according to the manufacturer’s
instructions. Two days after transfection, recombinant
virus was harvested.
Viral replication experiments
To investigate the RC of the NC/p1 mutants, viral repli-
cation curves were generated. For each 293 T cell
recombinant virus batch the amount of p24 was deter-
mined by ELISA (AMPAK™, DAKO, Cambridgeshire,
UK) [31,32]. Viral replication experiments were per-
formed by infecting 2.0 × 106 SupT1 cells with 100 ng
of p24 of each recombinant virus batch. After two hours
of incubation, the cells were washed twice with RPMI
1640 medium with L-glutamine (Cambrex, Verviers, Bel-
gium) and resuspended in 10 ml culture medium (RPMI
1640 medium with L-glutamine supplemented with 10%
FCS (Gibco, Breda, The Netherlands) and gentamicin
(10 μg/ml, Invitrogen, Breda, The Netherlands). Cultures
were maintained for 13 days and at day 0-7, 9, 10, and
13, two times 150 μl of cell-free viral supernatant was
taken for p24 analysis.
In vitro evolution experiments
In vitro evolution experiments were performed in five-
fold for all NC/p1 mutants. For this SupT1 cells (2.0 ×
106) were infected with 250 μl recombinant virus in an
initial volume of 1 ml culture medium. After 1 h incuba-
tion at 37°C, 9 ml of culture medium were added. Cul-
tures were replenished with fresh culture medium twice
weekly. When full-blown cytopathogenic effects (CPE)
were observed, the virus was harvested, and approxi-
mately 12.5 - 250 μl were used to perform a new passage.
After 10 passages, all Gag cleavage sites and the complete
C-terminus of Gag (p2-NC-p1-p6) and protease were
amplified from viral RNA and sequenced, as described
previously [18,31]. Dominant amino acid changes com-
pared to the original NC/p1 mutants were scored.
Quantitative Western blot analysis
Recombinant NC/p1 HIV-1 molecular clones were used to
transfect 293 T cells in the absence and presence of var-
ious concentrations of RO033-4649 using Lipofectamine
2000 (Invitrogen). After 48 h, culture medium was har-
vested, and virus particles were collected from cleared
media by centrifugation at 17.000 rpm for 1 h at 4°C (Bio-
fuge, fixed-angle rotor #3332, Heraeus, Germany). For
Western blot analysis, viral supernatant was boiled in SDS
sample buffer, separated by 12% SDS-PAGE for MA and
CA analysis or by 16.5% Ready Gel Tris-Tricine gel (Bio-
Rad, Veenendaal, The Netherlands) for NC analysis and
transferred to an Immobilon-FL membrane (Millipore B.
V., The Netherlands). The membrane was first probed
with either an anti-NC antibody obtained from Dr. Jeff Lif-
son from the AIDS and Cancer Virus Program (SAIC Fre-
derick, National Cancer Institute at Frederick, USA) or
with HIV-1SF2 p24 antiserum, obtained through the AIDS
Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH) or with an MA antiserum obtained
from Prof. H.-G. Kräusslich from the University of Heidel-
berg (Germany) after which the membrane was probed
with Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen).
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Subsequently, quantitative Western blot analysis was per-
formed using the Odyssey Infrared Imaging System as
recommended by the manufacturer (LI-COR Biosciences,
Munich, Germany).
Drug susceptibility analysis
To determine drug susceptibility of the recombinant
viruses, the infectious virus titre (TCID50) was determined
using end-point dilutions in MT-2 cells. Subsequently,
drug susceptibility of these viruses was determined in
duplicate using the multiple cycle MTT assay [33].
Hydrolysis of NC/p1 peptides
Peptides mimicking the wild-type and mutated cleavage
site of NC/p1 were synthesized by the Peptide Synthesis
Unit at the Institute of Organic Chemistry and Biochemis-
try, Academy of Sciences, Prague, Czech Republic. Clea-
vage of these peptides by wild-type HIV-1 PR was assayed
at 37°C in 100 mM acetate buffer, pH 4.7, and 100 mM
NaCl, using 500 nM HIV-1 PR (expressed and purified as
previously described) and 200 μM substrate [34-36]. Reac-
tions were allowed to proceed for 20-60 min, which corre-
sponds to less than 15% substrate turnover under these
conditions, and were stopped by addition of formic acid to
a final concentration of 2%. Reactions were centrifuged at
13000 g for 10 min and then analyzed by HPLC. An Agi-
lent 1200 HPLC system with an Agilent Zorbax SB-C18
RRHT threaded column thermostated at 60°C was used
for separation of reaction mixtures. A gradient of 2% to
33% acetonitrile supplemented with 0.1% formic acid was
used as a mobile phase. Separation was performed using a
flow rate of 1.3 ml/min, and the duration of the gradient
(6-16 min) was adjusted depending on the peptide so as to
achieve separation between substrate and products. Sub-
strate hydrolysis was quantified by integration of the sub-
strate peaks and normalized with respect to wild-type,
which was set to 100.
Determination of NC/p1 peptide hydrolysis products
An Agilent preparative 1200 system, with an Agilent Zor-
bax SB-C18 RRHT threaded column, was used to sepa-
rate and collect the NC/p1 peptide hydrolysis products.
The identity of these hydrolysis products was determined
by amino acid analysis and independently confirmed by
LC-MS (hybrid FTMS mass spectrometer LTQ Orbitrap
XL (Thermo Scientific) coupled with UHPLC system
RHEOS Allegro (Flux Instruments) with ACQUITY
UPLC BEH C18 (1.7 um × 2.1 mm × 150 mm) column
(Waters)). Samples were measured in electro spray posi-
tive mode.
The peptides corresponding to the cleavage products
identified by these analyses were synthesized and used
as retention markers in the HPLC-based assay described
above.
Molecular modeling and simulations
The effect of NC/p1 substrate mutations on PR-substrate
binding (Km effect) was investigated in seven PR/substrate
complexes (wild-type NC/p1, HXB2437T, HXB2437V,
HXB2436E+437T, HXB2436E+437T+438R, HXB2435R+436E+437T,
and HXB2431V) using molecular modeling and simulations.
The starting geometry was taken from the crystal structure
of an inactive (D25N) wild-type HIV-1 PR complexed with
the NC-p1 substrate peptide (PDB code: 2FNS)[29]. For
substrate residues outside the well-defined S3-S3’ PR
pockets, no experimental electron densities had been
observed. We thus modeled the flanking amino acids on
both unprimed and primed sides to yield the tridecapep-
tides studied experimentally. The residues were added so
as not to clash with van der Waals surface of PR visualized
with Insight II package (Insight II; Accelrys Software Inc.,
2000) nor with the crystallographic waters that were all
included in the model.
The seven PR and NC/p1 complexes were set up for
calculations, relaxed and solvated in a box of water
molecules (details can be found in Additional file 5).
Molecular dynamics simulations consisted of three
steps: i) gradual warming to 300 K over 50 ps, ii) equili-
bration at 300 K for 200 ps and iii) production run at
300 K for 1 ns. Snapshots of the trajectory were saved
every 1 ps.
The binding energies between the PR and the sub-
strates were calculated using the molecular mechanics-
generalized Born/surface area (MM-GBSA) methodology
using the MM-PBSA and SANDER modules of AMBER
8 (D.A. Case, T.A. Darden, T.E. Cheatham, III, C.L. Sim-
merling, J. Wang, R.E. Duke, R. Luo, K.M. Merz, B.
Wang, D.A. Pearlman, M. Crowley, S. Brozell, V. Tsui,
H. Gohlke, J. Mongan, V. Hornak, G. Cui, P. Beroza, C.
Schafmeister, J.W. Caldwell, W.S. Ross, and P.A. Koll-
man (2004), AMBER 8, University of California, San
Francisco)[37]. Energies of the complex, PR and sub-
strate (Ecplx, EPR, and Esubstr, respectively) were evaluated
for 100 snapshots (every 5 ps) from the second half of
the trajectory. Their differences (i.e. Ecplx - EPR - Esubstr)
were averaged to yield the total PR-substrate interaction
energies. These were further decomposed to contribu-
tions from individual amino acids.
Additional material
Additional file 1: Viral replication curves of HXB2431V and HXB2429K
+431V as observed during in vitro evolution experiments of
HXB2431V.
Additional file 2: Quantitative Western blot analysis of NC/p1
mutants using a CA antiserum.
Additional file 3: Residue positional fluctuations of substrates in
complex with PR during molecular dynamics simulations.
Additional file 4: Interaction energy between PR and substrate
variants for tridecameric peptides and P3-P3’ residues.
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Additional file 5: Molecular modeling and simulations of PR-
substrate complexes.
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